Macrogenics vs Nuvation Bio
Macrogenics is the larger business, with $150m of revenue in fiscal 2025 against $62.9m for Nuvation Bio (2.4 times as much). Nuvation Bio grew faster (699.0% against -0.3%). Macrogenics kept more of each dollar of sales as profit: a net margin of -49.9% against -325.3%. Macrogenics carries less debt relative to equity (0.0% against 17.3%).
| Latest fiscal year | MacrogenicsMGNX, 2025 | Nuvation BioNUVB, 2025 |
|---|---|---|
| Revenue | $150m | $62.9m |
| Revenue growth | -0.3% | 699.0% |
| Net income | −$74.6m | −$205m |
| Operating margin | -48.7% | -338.7% |
| Net margin | -49.9% | -325.3% |
| Return on equity | -86.9% | -53.2% |
| Free cash flow | −$83.0m | −$181m |
| Cash | $57.2m | $164m |
| Total debt | $0 | $52.9m |
| Debt to equity | 0.0% | 17.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 293 | 298 |
| Market value | $149m | $1.61bn |
| Price vs our value range | — | — |
| Moat score | 29 (Weak) | — |
| Insider trades, 12 months | 0 buys, 1 sales | 1 buys, 16 sales |